O 6-methylguanine-DNA methyltransferase (MGMT): Impact on cancer risk in response to tobacco smoke

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 736, Issue 1-2, 2012, Pages 64-74

  Christmann, Markus ^a   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Biomarker; Cancer protection; DNA repair; Lung cancer; MGMT; Tobacco

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TOBACCO SMOKE;

BLADDER CANCER; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; DNA METHYLATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTOXICITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MGMT GENE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SMOKING; STOMACH CANCER; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; UPREGULATION; UTERINE CERVIX CANCER;

CARCINOGENS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK; SMOKE; SMOKING; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; MUS MUSCULUS; NICOTIANA TABACUM; RATTUS;

EID: 84864506377     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2011.06.004     Document Type: Review

References (152)

1. Doll R., Hill A.B. Smoking and carcinoma of the lung; preliminary report. Br. Med. J. 1950, 2:739-748.
2. Wynder E.L., Graham E.A. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. J. Am. Med. Assoc. 1950, 143:329-336.
3. Sasco A.J., Secretan M.B., Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004, 45(Suppl. 2):S3-S9.
4. Gandini S., Botteri E., Iodice S., Boniol M., Lowenfels A.B., Maisonneuve P., Boyle P. Tobacco smoking and cancer: a meta-analysis. Int. J. Cancer 2008, 122:155-164.
5. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Tobacco smoke and Involuntary Smoking, vol. 83. Lyon: IARC Press, 2004.
6. Duckrey H., Preussmann R. Die Naturwissenschaften 1962, 49:498-499.
7. Rhoades J.W., Johnson D.E. N-dimethylnitrosamine in tobacco smoke condensate. Nature 1972, 236:307-308.
8. Lijinsky W. N-Nitroso compounds in the diet. Mutat. Res. 1999, 443:129-138.
9. Hecht S.S. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res. 1999, 424:127-142.
10. Hecht S.S., Chen C.B., Hirota N., Ornaf R.M., Tso T.C., Hoffmann D. Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice. J. Natl. Cancer Inst. 1978, 60:819-824.
11. Hecht S.S., Rivenson A., Braley J., DiBello J., Adams J.D., Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res. 1986, 46:4162-4166.
12. Hecht S.S., Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988, 9:875-884.
13. Fischer S., Castonguay A., Kaiserman M., Spiegelhalder B., Preussmann R. Tobacco-specific nitrosamines in Canadian cigarettes. J. Cancer Res. Clin. Oncol. 1990, 116:563-568.
14. Fischer S., Spiegelhalder B., Preussmann R. Tobacco-specific nitrosamines in European and USA cigarettes. Arch. Geschwulstforsc. 1990, 60:169-177.
15. Fischer S., Spiegelhalder B., Eisenbarth J., Preussmann R. Investigations on the origin of tobacco-specific nitrosamines in mainstream smoke of cigarettes. Carcinogenesis 1990, 11:723-730.
16. Adams J.D., Lee S.J., Hoffmann D. Carcinogenic agents in cigarette smoke and the influence of nitrate on their formation. Carcinogenesis 1984, 5:221-223.
17. Hoffmann D., Adams J.D., Brunnemann K.D., Hecht S.S. Assessment of tobacco-specific N-nitrosamines in tobacco products. Cancer Res. 1979, 39:2505-2509.
18. Brunnemann K.D., Fink W., Moser F. Analysis of volatile N-nitrosamines in mainstream and sidestream smoke from cigarettes by GLC-TEA. Oncology 1980, 37:217-222.
19. Tricker A.R., Ditrich C., Preussmann R. N-nitroso compounds in cigarette tobacco and their occurrence in mainstream tobacco smoke. Carcinogenesis 1991, 12:257-261.
20. Beranek D.T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res. 1990, 231:11-30.
21. Hecht S.S., Trushin N., Castonguay A., Rivenson A. Comparative tumorigenicity and DNA methylation in F344 rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N-nitrosodimethylamine. Cancer Res. 1986, 46:498-502.
22. 6-methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis in A/J mouse lung. Cancer Res. 1991, 51:5557-5564.
23. Lao Y., Villalta P.W., Sturla S.J., Wang M., Hecht S.S. Quantitation of pyridyloxobutyl DNA adducts of tobacco-specific nitrosamines in rat tissue DNA by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Chem. Res. Toxicol. 2006, 19:674-682.
24. 6-alkylguanine DNA adducts by recombinant human DNA polymerases. J. Biol. Chem. 2006, 281:38244-38256.
25. Pauly G.T., Peterson L.A., Moschel R.C. Mutagenesis by O(6)-[4-oxo-4-(3-pyridyl)butyl]guanine in Escherichia coli and human cells. Chem. Res. Toxicol. 2002, 15:165-169.
26. 6-pyridyloxobutylguanine adducts contribute to the mutagenic properties of pyridyloxobutylating agents. Chem. Res. Toxicol. 2005, 18:1619-1625.
27. Trushin N., Rivenson A., Hecht S.S. Evidence supporting the role of DNA pyridyloxobutylation in rat nasal carcinogenesis by tobacco-specific nitrosamines. Cancer Res. 1994, 54:1205-1211.
28. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol. 1995, 51:167-223.
29. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990, 50:6119-6129.
30. Pegg A.E. Repair of O(6)-alkylguanine by alkyltransferases. Mutat. Res. 2000, 462:83-100.
31. 6-methylguanine. Cancer Res. 1993, 53:2780-2785.
32. 6-alkylguanine-DNA alkyltransferase. Chem. Res. Toxicol. 1997, 10:562-567.
33. 6-alkylguanine-DNA alkyltransferase. Chem. Res. Toxicol. 1999, 12:127-131.
34. 6-[4-oxo-4-(3-pyridyl)butyl]guanine, is detected in tissues from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-treated A/J mice. Chem. Res. Toxicol. 2003, 16:1-6.
35. Li L., Perdigao J., Pegg A.E., Lao Y., Hecht S.S., Lindgren B.R., Reardon J.T., Sancar A., Wattenberg E.V., Peterson L.A. The influence of repair pathways on the cytotoxicity and mutagenicity induced by the pyridyloxobutylation pathway of tobacco-specific nitrosamines. Chem. Res. Toxicol. 2009, 22:1464-1472.
36. Brown P.J., Bedard L.L., Massey T.E. Repair of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA pyridyloxobutylation by nucleotide excision repair. Cancer Lett. 2008, 260:48-55.
37. Brown P.J., Massey T.E. In vivo treatment with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces organ-specific alterations in in vitro repair of DNA pyridyloxobutylation. Mutat. Res. 2009, 663:15-21.
38. Xu-Welliver M., Pegg A.E. Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase. Carcinogenesis 2002, 23:823-830.
39. Becker K., Dosch J., Gregel C.M., Martin B.A., Kaina B. Targeted expression of human O(6)-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. Cancer Res. 1996, 56:3244-3249.
40. Becker K., Gregel C., Fricke C., Komitowski D., Dosch J., Kaina B. DNA repair protein MGMT protects against N-methyl-N-nitrosourea-induced conversion of benign into malignant tumors. Carcinogenesis 2003, 24:541-546.
41. 6-methylguanine-DNA methyltransferase protects against skin tumor formation induced by antineoplastic chloroethylnitrosourea. Cancer Res. 1997, 57:3335-3338.
42. 6-methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:6468-6472.
43. Sakumi K., Shiraishi A., Shimizu S., Tsuzuki T., Ishikawa T., Sekiguchi M. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. Cancer Res. 1997, 57:2415-2418.
44. Liu L., Qin X., Gerson S.L. Reduced lung tumorigenesis in human methylguanine DNA--methyltransferase transgenic mice achieved by expression of transgene within the target cell. Carcinogenesis 1999, 20:279-284.
45. 6-alkylguanine-DNA alkyltransferase. Science 1993, 259:219-222.
46. 6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res. 1994, 54:4648-4652.
47. 6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis. Carcinogenesis 2010, 31:2111-2117.
48. Kaina B., Christmann M., Naumann S., Roos W.P. MGMT: key node in the battle against genotoxicity carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst.) 2007, 6:1079-1099.
49. Margison G.P., Povey A.C., Kaina B., Santibanez M.F. Koref Variability and regulation of O(6)-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003, 24:625-635.
50. Gerson S.L. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 2002, 20:2388-2399.
51. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 2008, 26:4189-4199.
52. Weller M., Stupp R., Reifenberger G., Brandes A.A., van den Bent M.J., Wick W., Hegi M.E. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat. Rev. Neurol. 2009.
53. Kaina B., Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int. J. Clin. Pharmacol. Ther. 2002, 40:354-367.
54. Kaina B., Margison G.P., Christmann M. Targeting O-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol. Life Sci. 2010, 67:3663-3681.
55. Costello J.F., Futscher B.W., Kroes R.A., Pieper R.O. Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines. Mol. Cell. Biol. 1994, 14:6515-6521.
56. 6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J. Biol. Chem. 1994, 269:17228-17237.
57. 6-methylguanine-DNA methyltransferase gene. Nucleic Acids Res. 1991, 19:6163-6167.
58. 6-methylguanine-DNA methyltransferase promoter: correlation with gene suppression. Carcinogenesis 1995, 16:1385-1390.
59. 6-methylguanine-DNA methyltransferase gene. Cancer Res. 1997, 57:3672-3677.
60. 6-methylguanine DNA methyltransferase gene is associated with the loss of nucleosome-like positioning. Mol. Cell. Biol. 1997, 17:5813-5822.
61. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell. Biol. 1997, 17:5612-5619.
62. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9821-9826.
63. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999, 59:67-70.
64. 6-methylguanine-DNA methyltransferase gene in cultured human tumor cells. Mutat. Res. 1992, 273:221-230.
65. Christmann M., Pick M., Lage H., Schadendorf D., Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int. J. Cancer 2001, 92:123-129.
66. 6-alkylguanine DNA repair activity during continuous exposure to carcinogen. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:5499-5502.
67. 6-methylguanine-DNA-methyltransferase activity induced by various treatments in mammalian cells. Cancer Res. 1986, 46:5701-5705.
68. 6-methylguanine-DNA-methyltransferase activity of rat hepatoma cells is increased after a single exposure to alkylating agents. Carcinogenesis 1987, 8:91-95.
69. 6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol. Cell. Biol. 1991, 11:4660-4668.
70. 6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in rat liver cells exhibiting different status of differentiation. Biochim. Biophys. Acta 1995, 1270:63-72.
71. Grombacher T., Mitra S., Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 1996, 17:2329-2336.
72. 6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene 1996, 12:693-697.
73. 6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene 1998, 17:845-851.
74. 6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling. Cancer Res. 1998, 58:3950-3956.
75. Lavon I., Fuchs D., Zrihan D., Efroni G., Zelikovitch B., Fellig Y., Siegal T. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res. 2007, 67:8952-8959.
76. 6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours. Br. J. Cancer 1995, 71:37-39.
77. 6-methylguanine-DNA methyltransferase in human melanoma metastases. Eur. J. Cancer 1997, 33:129-134.
78. 6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol. Rep. 2010, 23:1269-1276.
79. Christmann M., Nagel G., Horn S., Krahn U., Wiewrodt D., Sommer C., Kaina B. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int. J. Cancer 2010, 127:2106-2118.
80. Wiewrodt D., Nagel G., Dreimuller N., Hundsberger T., Perneczky A., Kaina B. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int. J. Cancer 2008, 122:1391-1399.
81. Kitange G.J., Carlson B.L., Schroeder M.A., Grogan P.T., Lamont J.D., Decker P.A., Wu W., James C.D., Sarkaria J.N. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009, 11:281-291.
82. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J. Neurochem. 2006, 96:766-776.
83. Inoue R., Abe M., Nakabeppu Y., Sekiguchi M., Mori T., Suzuki T. Characterization of human polymorphic DNA repair methyltransferase. Pharmacogenetics 2000, 10:59-66.
84. 6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br. J. Cancer 2003, 89:1517-1523.
85. 6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells. Carcinogenesis 2005, 26:1473-1480.
86. 6-alkylguanine-DNA alkyltransferase variants. Chem. Res. Toxicol. 2004, 17:424-434.
87. Mijal R.S., Kanugula S., Vu C.C., Fang Q., Pegg A.E., Peterson L.A. DNA sequence context affects repair of the tobacco-specific adduct O(6)-[4-Oxo-4-(3-pyridyl)butyl]guanine by human O(6)-alkylguanine-DNA alkyltransferases. Cancer Res. 2006, 66:4968-4974.
88. 6-alkylguanine-DNA alkyltransferase: identification of a missense variation in the active site region. Pharmacogenetics 1999, 9:81-87.
89. 6-alkylguanine-DNA alkyltransferase. Biochem. Pharmacol. 2008, 75:618-626.
90. Teo A.K., Oh H.K., Ali R.B., Li B.F. The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage. Mol. Cell. Biol. 2001, 21:7105-7114.
91. 6-methylguanine-DNA-methyltransferase (MGMT) gene increase human sensitivity to the genotoxic effects of the tobacco-specific nitrosamine carcinogen NNK. Pharmacogenet. Genomics 2005, 15:571-578.
92. 6-methylguanine-DNA-methyltransferase (MGMT) gene is associated with increased hypoxanthine phosphoribosyltransferase (HPRT) mutant frequency in lymphocytes of tobacco smokers. Pharmacogenet. Genomics 2007, 17:743-753.
93. 6-methylguanine-DNA methyltransferase activity in human buccal mucosal tissue and cell cultures. Complex mixtures related to habitual use of tobacco and betel quid inhibit the activity in vitro. Carcinogenesis 1997, 18:1889-1895.
94. Janssen K., Eichhorn-Grombacher U., Schlink K., Nitzsche S., Oesch F., Kaina B. Long-time expression of DNA repair enzymes MGMT and APE in human peripheral blood mononuclear cells. Arch. Toxicol. 2001, 75:306-312.
95. Jacob R., Shafiei N., Nagel G., Welkoborsky H.J., Mann W., Kaina B. MGMT activity in mucosal epithelium and squamous cell carcinoma of the head and neck. Anticancer Res. 2010, 30:2561-2566.
96. 6-alkylguanine-DNA alkyltransferase activity in human lung tissue. Carcinogenesis 1994, 15:1535-1539.
97. 6-alkylguanine-DNA alkyltransferase activity in bronchial epithelial cells. Int. J. Cancer 2006, 119:463-466.
98. Rodriguez M.J., Acha A., Ruesga M.T., Rodriguez C., Rivera J.M., Aguirre J.M. Loss of expression of DNA repair enzyme MGMT in oral leukoplakia and early oral squamous cell carcinoma. A prognostic tool?. Cancer Lett. 2007, 245:263-268.
99. 6-methylguanine-DNA methyltransferase expression in human lung carcinomas. Carcinogenesis 1998, 19:1247-1250.
100. Nozoe T., Korenaga D., Kabashima A., Sugimachi K. Smoking-related increase of O(6)-methylguanine-DNA methyltransferase expression in squamous cell carcinoma of the esophagus. Cancer Lett. 2002, 184:49-55.
101. Povey A.C., Hall C.N., Cooper D.P., O'Connor P.J., Margison G.P. Determinants of O(6)-alkylguanine-DNA alkyltransferase activity in normal and tumour tissue from human colon and rectum. Int. J. Cancer 2000, 85:68-72.
102. Toyooka S., Maruyama R., Toyooka K.O., McLerran D., Feng Z., Fukuyama Y., Virmani A.K., Zochbauer-Muller S., Tsukuda K., Sugio K., Shimizu N., Shimizu K., Lee H., Chen C.Y., Fong K.M., Gilcrease M., Roth J.A., Minna J.D., Gazdar A.F. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int. J. Cancer 2003, 103:153-160.
103. Liu Y., Lan Q., Siegfried J.M., Luketich J.D., Keohavong P. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 2006, 8:46-51.
104. 6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res. 2003, 63:4842-4848.
105. Puri S.K., Si L., Fan C.Y., Hanna E. Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am. J. Otolaryngol. 2005, 26:12-17.
106. Stepanov I., Hecht S.S., Ramakrishnan S., Gupta P.C. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. Int. J. Cancer 2005, 116:16-19.
107. Cogliano V., Straif K., Baan R., Grosse Y., Secretan B., Ghissassi El.F. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol. 2004, 5:708.
108. Sawhney M., Rohatgi N., Kaur J., Gupta S.D., Deo S.V., Shukla N.K., Ralhan R. MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis. Oral Oncol. 2007, 43:515-522.
109. 6-methylguanine DNA methyltransferase by promoter hypermethylation and its relationship to betel quid chewing in oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010, 109:883-889.
110. Lin R.K., Hsieh Y.S., Lin P., Hsu H.S., Chen C.Y., Tang Y.A., Lee C.F., Wang Y.C. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J. Clin. Invest. 2010, 120:521-532.
111. 6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue. Cancer Detect. Prev. 1996, 20:130-136.
112. 6-alkylguanine-DNA alkyltransferase. DNA Repair (Amst.) 2007, 6:1071-1078.
113. Bugni J.M., Han J., Tsai M.S., Hunter D.J., Samson L.D. Genetic association and functional studies of major polymorphic variants of MGMT. DNA Repair (Amst.) 2007, 6:1116-1126.
114. 6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 2000, 9:339-342.
115. Shen M., Purdue M.P., Kricker A., Lan Q., Grulich A.E., Vajdic C.M., Turner J., Whitby D., Chanock S., Rothman N., Armstrong B.K. Polymorphisms in DNA repair genes and risk of non-Hodgkin's lymphoma in New South Wales, Australia. Haematologica 2007, 92:1180-1185.
116. Huang J., Ye F., Chen H., Lu W., Xie X. Amino acid substitution polymorphisms of the DNA repair gene MGMT and the susceptibility to cervical carcinoma. Carcinogenesis 2007, 28:1314-1322.
117. Liu Y., Scheurer M.E., El-Zein R., Cao Y., Do K.A., Gilbert M., Aldape K.D., Wei Q., Etzel C., Bondy M.L. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol. Biomarkers Prev. 2009, 18:204-214.
118. Felini M.J., Olshan A.F., Schroeder J.C., North K.E., Carozza S.E., Kelsey K.T., Liu M., Rice T., Wiencke J.K., Wrensch M.R. DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology 2007, 29:55-58.
119. Hall J., Hashibe M., Boffetta P., Gaborieau V., Moullan N., Chabrier A., Zaridze D., Shangina O., Szeszenia-Dabrowska N., Mates D., Janout V., Fabianova E., Holcatova I., Hung R.J., McKay J., Canzian F., Brennan P. The association of sequence variants in DNA repair and cell cycle genes with cancers of the upper aerodigestive tract. Carcinogenesis 2007, 28:665-671.
120. 6-methylguanine DNA methyltransferase and breast cancer risk. Pharmacogenet. Genomics 2006, 16:469-474.
121. Doecke J., Zhao Z.Z., Pandeya N., Sadeghi S., Stark M., Green A.C., Hayward N.K., Webb P.M., Whiteman D.C. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int. J. Cancer 2008, 123:174-180.
122. 6-methylguanine-DNA methyltransferase-codon 178 genetic polymorphism. Lung Cancer 2004, 44:281-286.
123. 6-methylguanine-DNA methyltransferase gene coding region polymorphisms and oral cancer risk. J. Oral Pathol. Med. 2010, 39:645-650.
124. Stern M.C., Conti D.V., Siegmund K.D., Corral R., Yuan J.M., Koh W.P., Yu M.C. DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2363-2372.
125. Huang W.Y., Chow W.H., Rothman N., Lissowska J., Llaca V., Yeager M., Zatonski W., Hayes R.B. Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis 2005, 26:1354-1359.
126. 6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and risk of colorectal cancer in the Nurses' Health Study and Physicians' Health Study (United States). Cancer Causes Control 2006, 17:721-731.
127. Huang W.Y., Olshan A.F., Schwartz S.M., Berndt S.I., Chen C., Llaca V., Chanock S.J., Fraumeni J.F., Hayes R.B. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1747-1753.
128. 6-methylguanine DNA methyltransferase and endometrial cancer risk. Carcinogenesis 2006, 27:2281-2285.
129. Krzesniak M., Butkiewicz D., Samojedny A., Chorazy M., Rusin M. Polymorphisms in TDG and MGMT genes - epidemiological and functional study in lung cancer patients from Poland. Ann. Hum. Genet. 2004, 68:300-312.
130. Zhang Z., Wang L., Wei S., Liu Z., Wang L.E., Sturgis E.M., Wei Q. Polymorphisms of the DNA repair gene MGMT and risk and progression of head and neck cancer. DNA Repair (Amst.) 2010, 9:558-566.
131. 6-methylguanine-DNA methyltransferase and risk of bladder cancer in southern China: a case-control analysis. Cancer Lett. 2005, 227:49-57.
132. 6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis. Mutagenesis 2010, 25:83-95.
133. Shen J., Terry M.B., Gammon M.D., Gaudet M.M., Teitelbaum S.L., Eng S.M., Sagiv S.K., Neugut A.I., Santella R.M. MGMT genotype modulates the associations between cigarette smoking, dietary antioxidants and breast cancer risk. Carcinogenesis 2005, 26:2131-2137.
134. 6-methylguanine-DNA methyltransferase with risk of lung cancer in non-Hispanic Whites. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2364-2369.
135. 6-alkylguanine DNA alkyltransferase gene and lung cancer risk in non-smokers exposed to second-hand smoke. Cancer Epidemiol. Biomarkers Prev. 2004, 13:320-323.
136. 6-alkylguanine-DNA alkyltransferase. Int. J. Cancer 2008, 122:791-795.
137. Loh Y.H., Mitrou P.N., Bowman R., Wood A., Jeffery H., Luben R.N., Lentjes M.A., Khaw K.T., Rodwell S.A. MGMT Ile143Val polymorphism dietary factors and the risk of breast, colorectal and prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study. DNA Repair (Amst.) 2010, 9:421-428.
138. 6-alkylguanine and O4-alkylthymine and the mutagenic properties of these bases. Mutat. Res. 1990, 233:81-94.
139. Riely G.J., Kris M.G., Rosenbaum D., Marks J., Li A., Chitale D.A., Nafa K., Riedel E.R., Hsu M., Pao W., Miller V.A., Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 2008, 14:5731-5734.
140. Hackman P., Hou S.M., Nyberg F., Pershagen G., Lambert B. Mutational spectra at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus in T-lymphocytes of nonsmoking and smoking lung cancer patients. Mutat. Res. 2000, 468:45-61.
141. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21:7435-7451.
142. Le Calvez F., Mukeria A., Hunt J.D., Kelm O., Hung R.J., Taniere P., Brennan P., Boffetta P., Zaridze D.G., Hainaut P. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005, 65:5076-5083.
143. Belinsky S.A., Devereux T.R., Maronpot R.R., Stoner G.D., Anderson M.W. Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res. 1989, 49:5305-5311.
144. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996, 274:430-432.
145. Smith L.E., Denissenko M.F., Bennett W.P., Li H., Amin S., Tang M., Pfeifer G.P. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J. Natl. Cancer Inst. 2000, 92:803-811.
146. Ronai Z.A., Gradia S., Peterson L.A., Hecht S.S. G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis 1993, 14:2419-2422.
147. Peterson L.A. Formation, repair, and genotoxic properties of bulky DNA adducts formed from tobacco-specific nitrosamines. J. Nucleic Acids 2010, 2010.
148. Wood M.L., Dizdaroglu M., Gajewski E., Essigmann J.M. Mechanistic studies of ionizing radiation and oxidative mutagenesis: genetic effects of a single 8-hydroxyguanine (7-hydro-8-oxoguanine) residue inserted at a unique site in a viral genome. Biochemistry 1990, 29:7024-7032.
149. Moriya M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted GC→TA transversions in simian kidney cells. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1122-1126.
150. Rosa J.G., Prokopczyk B., Desai D.H., Amin S.G., El-Bayoumy K. Elevated 8-hydroxy-2'-deoxyguanosine levels in lung DNA of A/J mice and F344 rats treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and inhibition by dietary 1,4-phenylenebis(methylene)selenocyanate. Carcinogenesis 1998, 19:1783-1788.
151. Azad N., Rojanasakul Y., Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J. Toxicol. Environ. Health B: Crit. Rev. 2008, 11:1-15.
152. Sandercock L.E., Hahn J.N., Li L., Luchman H.A., Giesbrecht J.L., Peterson L.A., Jirik F.R. Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis 2008, 29:866-874.